AlbertRK, LakshminarayanS, HildebrandtJ, KirkW, and ButlerJ. (1979). Increased surface tension favors pulmonary edema formation in anesthetized dog lungs. J Clin Invest, 63:1015–1018.
2.
BärtschP, and GibbsJSR. (2007). Effect of altitude on the heart and the lungs. Circulation, 116:2191–2202.
3.
BärtschP, MaggioriniM, RitterM, NotiC, VockP, and OelzO. (1991). Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med, 325:1284–1289.
4.
BärtschP, MairbäurlH, MaggioriniM, and SwensonER. (2005). Physiological aspects of high-altitude pulmonary edema. J Appl Physiol, 98:1101–1110.
5.
BärtschP, VockP, and FranciolliM. (1990). High altitude pulmonary edema after successful treatment of acute mountain sickness with dexamethasone. J Wilderness Med, 1:162–164.
6.
BjertnaesLJ, and VaageJ. (1996). Methylprednisolone attenuates hypoxic pulmonary vasoconstriction in man. Intensive Care Med, 22:715–717.
7.
BorgT, GerdinB, and ModigJ. (1985). Prophylactic and delayed treatment with high-dose methylprednisolone in a porcine model of early ARDS induced by endotoxaemia. Acta Anaesthesiol Scand, 29:831–845.
8.
BoumpasDT. (1996). A novel action of glucocorticoids—NF-kappa B inhibition. Br J Rheumatol, 35:709–710.
9.
DehnertC, BergerMM, MairbäurlH, and BärtschP. (2007). High altitude pulmonary edema: A pressure-induced leak. Respir Physiol Neurobiol, 158:266–273.
10.
EhrchenJ, SteinmullerL, BarczykK, TenbrockK, NackenW, EisenacherM, NordhuesU, SorgC, SunderkotterC, and RothJ. (2007). Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood, 109:1265–1274.
11.
FroniusM. (2013). Treatment of pulmonary edema by ENaC activators/stimulators. Curr Mol Pharmacol, 6:13–27.
12.
HackettPH, RoachRC, WoodRA, FoutchRG, MeehanRT, RennieD, and MillsWJJr. (1988). Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med, 59:950–954.
13.
Hafezi-MoghadamA, SimonciniT, YangZ, LimbourghFP, PlumierJC, RebsamenMC, HsiehCM, ChuiDS, ThomasKL, ProrockAJ, LaubachVE, MoskowitzMA, FrenchBA, LeyK, and LiaoJK. (2002). Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of nitric oxide synthase. Nature Med, 8:473–479.
14.
JaisX, LaunayD, YaiciA, Le PavecJ, TcherakianC, SitbonO, SimonneauG, aand HumbertM. (2008). Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. Arthritis Rheum, 58:521–531.
15.
KatoM, KataokaH, OdaniT, FujiedaY, OtomoK, OkuK, HoritaT, YasudaS, AtsumiT, OhiraH, TsujinoI, NishimuraM, and KoikeT. (2011). The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases: Report of five cases and a literature review. Lupus, 20:1047–1056.
16.
KriemlerS, KohlerM, ZehnderM, BlochKE, and Brunner-La RoccaH. (2006). Successful treatment of severe acute mountain sickness and excessive pulmonary hypertension with dexamethasone in a prepubertal girl. High Alt Med Biol, 7:256–261.
17.
LangF, and ShumilinaE. (2013). Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1. FASEB J, 27:3–12.
18.
LiuC, CroftQP, KalidharS, BrooksJT, HerigstadM, SmithTG, DorringtonKL, and RobbinsPA. (2013). Dexamethasone mimics aspects of physiological acclimatization to 8 hours of hypoxia but suppresses plasma erythropoietin. J Appl Physiol (1985), 114:948–956.
19.
MaggioriniM, Brunner-La RoccaHP, PethS, FischlerM, BöhmT, BernheimA, KienckeS, BlochKE, DehnertC, NaeijeR, LehmannT, BartschP, and MairbaurlH. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema. Ann Intern Med, 145:497–506.
20.
MaggioriniM, KaufmannB, BöhmT, KienckeS, DeBoek BK. A, SchöbM, SiebenmannC, ZügelS, NussbaumerY. (2011). Dexamethasone decreases pulmonary arterial pressure and improves gas exchange while used for the treatment of AMS independently of HAPE susceptibility. International Hypoxia Symposium, Lake Louise.
21.
NaeijeR, and MelotC. (1990). Acute pulmonary oedema on the Ruwenzori mountain range. Br Heart J, 64:400–402.
22.
NodaM, SuzukiS, TsubochiH, SugitaM, MaedaS, KobayashiS, KuboH, and KondoT. (2003). Single dexamethasone injection increases alveolar fluid clearance in adult rats. Crit Care Med, 31:1183–1189.
23.
OgawaA, NakamuraK, MizoguchiH, FujiiN, FujioH, KusanoKF, OheT, and ItoH. (2011). Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med, 183:139–140.
24.
OppongE, FlinkN, and CatoAC. (2013). Molecular mechanisms of glucocorticoid action in mast cells. Mol Cell Endocrinol, 380:119–126.
25.
RomeroIA, RadewiczK, JubinE, MichelCC, GreenwoodJ, CouraudPO, and AdamsonP. (2003). Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett, 344:112–116.
26.
StahnC, and ButtgereitF. (2008). Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol, 4:525–533.
27.
SwensonER, MaggioriniM, MongovinS, GibbsJSR, GreveI, MairbäurlH, and BärtschP. (2002). Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. JAMA, 287:2228–2235.
28.
UnderwoodJL, MurphyCG, ChenJ, Franse-CarmanL, WoodI, EpsteinDL, and AlvaradoJA. (1999). Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol, 277:C330–342.
29.
WilliamsJS. (2013). Evolving research in nongenomic actions of aldosterone. Curr Opin Endocrinol Diabetes Obes, 20:198–203.
30.
YangS, and ZhangL. (2004). Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol, 2:1–12.
31.
YoungSL, and SilbajorisRA. (1986). Dexamethasone increases adult rat lung surfactant lipids. J Appl Physiol, 60:1665–1672.
